Search Within

Michael John Mauro

  1. "2024"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (3)
  3. Correspondence (2)
  4. Editorial (1)
Groups
  1. Adult Leukemia (17)
  2. Center for Hematologic Malignancies (17)
  3. Department of Medicine (17)
  4. Hematologic Malignancies, Division of (17)
  5. Advanced Practice Providers (1)
  6. Biostatistics Service (1)

More Groups

People
  1. Andriy Derkach (1)
  2. Ellin Berman (1)
  3. Eytan Stein (1)
  4. Marisa Hine (1)
  5. Raajit Rampal (1)
Years
  1. 2024 (17)
Publications
  1. Blood (9)
  2. Journal of Clinical Oncology (2)
  3. Leukemia (2)
  4. American Journal of Hematology (1)
  5. Clinical Cancer Research (1)
  6. Clinical Lymphoma, Myeloma and Leukemia (1)

More Publications

Publishers
  1. American Society of Hematology (9)
  2. American Society of Clinical Oncology (2)
  3. Nature Publishing Group (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Inc. (1)
  6. Future Medicine (1)

More Publishers

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First results of asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors for patients with chronic myeloid leukemia who do not achieve a deep molecular remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)
    Meeting Abstract

    Cortes, J. E.; Mauro, M. J.; Visotcky, A.; Tantravahi, S. K.; Thompson, J. E.; Yang, J.; Baim, A.; Gao, Y.; Maldonado-Schmidt, S.; Olig, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Zeidan, A. M.; Stein, E. M.; Mauro, M. J.; Podoltsev, N. A.; Rampal, R.
    Blood (2024)

    Fulltext@MSK | Save
  • Cardinal: A phase I, multicenter, open-label, dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in chronic myeloid leukemia
    Meeting Abstract

    Jabbour, E.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Hughes, T. P.; Kim, D. W.; Kantarjian, H. M.; Holes, L.; Kuriakose, E. T.; Mauro, M. J.
    Blood (2024)

    Fulltext@MSK | Save
  • Increased inflammatory cytokines in plasma are associated with sustained treatment-free remission in chronic myeloid leukaemia
    Meeting Abstract

    Kok, C. H.; Saunders, V. A.; Shanmuganathan, N.; Liu, L.; Irani, Y. D.; Clarson, J.; Dang, P.; Yeung, D. T.; Yong, A. S. M.; Branford, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the phase 2 ASC2ESCALAT trial in the cohort of patients (pts) after 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Atallah, E. L.; Levy, M. Y.; Koller, P. B.; Sasaki, K.; Tantravahi, S. K.; Andorsky, D.; Bremer, C. T.; Zeidner, J. F.; Luskin, M. R.; Munker, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Novel nilotinib tablet formulation: Pharmacokinetic characterization and effects of food
    Meeting Abstract

    Mauro, M. J.; Radich, J. P.; Jain, P.; Sequeira, D.; Douer, D.
    Blood (2024)

    Fulltext@MSK | Save
  • US expert consensus on defining intolerance to tyrosine kinase inhibitor treatment in chronic phase chronic myeloid leukemia (CML)
    Meeting Abstract

    Atallah, E. L.; Broder, M. S.; Chan, O.; Dalglish, H.; Flynn, K. E.; Gilreath, J.; Hine, M.; Hunter, A. M.; Mauro, M. J.; Pinilla-Ibarz, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • 5-year follow-up of the phase 2 optic study in patients with chronic-phase chronic myeloid leukemia: Efficacy, safety, and first end-of-treatment mutational results
    Meeting Abstract

    Cortes, J. E.; Deininger, M. W.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Asciminib provides long-term, durable molecular responses in patients with T3151-mutated CML-CP: Final analysis from a phase 1 trial
    Meeting Abstract

    Cortes, J. E.; Rea, D.; Mauro, M. J.; Hochhaus, A.; Kim, D. W.; Sasaki, K.; Lang, F.; Heinrich, M. C.; Breccia, M.; Deininger, M. W.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Dose-optimization study of 3 starting doses of ponatinib: Long-term results from the OPTIC trial
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save